ISPR — FY2026 Annual Report Analysis (fiscal year ended June 30, 2026)

Revenue down a quarter, and the shrinkage happened in the profitable half of the business

Ispire Technology (Nasdaq: ISPR) designs and sells vaping hardware — the devices and cartridges, not the liquid that goes in them. It runs two product lines: nicotine e-cigarettes sold worldwide under the Aspire brand through distributors, and cannabis vaporizer hardware sold in the US, Canada and South Africa on an ODM basis (the customer's brand goes on a device Ispire designs and builds). The company does not touch the cannabis plant itself.

For the fiscal year ended June 30, 2026, revenue fell 24.7% to $96.0 million from $127.5 million. The problem is not only the size of the decline but its composition: cannabis hardware, which the company states carries higher margins, fell 57.0% to $15.9 million and shrank from 29.0% to 16.6% of total revenue. Nicotine products fell a comparatively mild 11.5%, to $80.1 million. Gross profit — revenue minus what it costs to buy or build the product — fell nearly twice as fast as revenue, down 45.7% to $12.3 million.

Management attributes the revenue decline to three specific causes. US sales dropped $17.4 million (from $32.6 million to $15.1 million) because of "a tightening of our sales strategy which required higher upfront deposits and stricter payment terms, subsequently leading to a reduced participation from lower-tier accounts" — Ispire deliberately turned away customers it did not expect to get paid by. European sales fell $12.7 million (from $74.1 million to $61.4 million), which the filing ties to "European regulatory uncertainties regarding disposable bans and flavor restrictions, which led distributors to adopt a cautious purchasing strategy." Asia-Pacific excluding China fell $1.4 million. The UK's June 2025 ban on disposable e-cigarettes "caused the discontinuation of certain product lines," per the business section.

Margin compression came from mix and write-downs, not just price

Gross margin — the share of revenue left after the cost of the goods sold, before any overhead — fell from 17.8% to 12.8%. The filing names three drivers: "(i) competitive pricing pressures that lowered selling prices on certain products; (ii) an unfavorable shift in revenue mix, as our higher-margin cannabis vaping products sales decreased from 29.0% to 16.6% of total revenue...; and (iii) a significant increase in inventory write-downs, which expanded from $0.8 million in 2025 to $2.8 million in 2026, driven by a decline in expected sellable life of certain slow-moving products."

Only the first of those is a pricing problem. The second is the company losing its better business faster than its worse business, and the third is $2.0 million of incremental charges for product it now expects not to sell at full value — inventory net of write-downs ended the year at $3.1 million, down from $6.6 million.

The smaller loss is a cost-cutting result, not an operating recovery

Operating loss narrowed by $5.3 million even though gross profit fell $10.4 million. The entire swing, and more, came from operating expenses, which fell 25.8% ($15.6 million) to $44.9 million:

• General and administrative down $10.9 million (−36.2%) to $19.2 million, driven by roughly $5.0 million less payroll from North American headcount cuts, $2.5 million less legal and professional fees, and $2.2 million less stock-based compensation, again from headcount reduction.
• Sales and marketing down $3.4 million (−40.5%) to $5.0 million, mostly $2.8 million of North American marketing pulled back.
• Credit loss expense down only $1.3 million (−6.0%) to $20.7 million.

Research and development — already small — went from $363,301 to $81,035, a 78% cut. For a company whose stated differentiation is patented hardware technology, R&D of $81,000 against $96 million of revenue is close to a rounding error, though the filing notes much of the underlying development work is performed by its related-party supplier rather than in-house.

The pattern is that Ispire shrank its cost base faster than its gross profit, which is why the bottom line improved. Nothing in the filing indicates the underlying demand picture improved.

Getting paid remains the central problem

The single largest expense line below gross profit is not payroll or marketing — it is customers not paying. Credit loss expense (the charge a company books when it expects some invoices to go uncollected) was $20.7 million, or 21.6% of revenue, up from 17.3% a year earlier. Across FY2025 and FY2026 combined, Ispire booked $42.8 million of credit losses against $223.5 million of combined revenue — roughly 19 cents of every dollar billed.

The balance sheet shows how far this has gone. Gross accounts receivable fell to $46.0 million from $64.9 million, but the allowance against it — the cumulative reserve for amounts management does not expect to collect — rose to $26.1 million from $18.0 million. That means Ispire has now reserved 56.9% of what it is owed, up from 27.7% a year ago. Net receivables are $19.8 million, down from $47.0 million. The company also wrote off $12.5 million of receivables outright during the year, after $9.9 million in FY2025.

The filing is explicit that the improvement in provisioning is only partial: the decline "was the combined effect of the tightening of the North American sales strategy, including stricter payment terms and higher deposit requirements for new accounts, offset by the lack of improvement in long-aged customer balances." The newer business is being underwritten more carefully; the old cannabis-industry receivables are not recovering. A risk factor spells out why: "Most U.S. cannabis operators have significant debt which... may lead to insolvency or a takeover by creditors," and if capital does not return to the sector, "our cannabis operator customers may slow down or cease operations, and our ability to collect on accounts receivable may be negatively impacted."

Takeaway: Ispire's operating cash burn of just $0.6 million looks almost benign next to a $33.2 million net loss — but that gap exists because $20.7 million of the loss was a non-cash bad-debt provision and because the company is not paying its main supplier. It owes Shenzhen Yi Jia — 95%-owned by chairman and co-CEO Tuanfang Liu — a combined $76.3 million ($29.3 million in related-party payables plus $47.0 million reclassified as non-current). Shenzhen Yi Jia supplies 91% of Ispire's purchases and has agreed not to demand repayment of $22.0 million of that for twelve months from September 17, 2026. Ispire is being kept liquid by interest-free, unsecured trade credit from its own controlling shareholder's factory, not by its operations.

The balance sheet has crossed into deficit

Total stockholders' equity went from a positive $604,694 at June 30, 2025 to a negative $29,246,207 at June 30, 2026 — liabilities now exceed assets. Accumulated deficit reached $81.3 million against $52.3 million of paid-in capital. Total assets fell 37% to $64.3 million, while total liabilities barely moved, from $101.6 million to $93.5 million.

Working capital (current assets minus current liabilities, the rough measure of near-term solvency) was $0.8 million, up from $0.4 million — but only because current liabilities shrank $27.9 million, essentially in line with the $27.5 million decline in current assets. Of that liability reduction, $22.0 million was not paid down at all; it was moved from current to non-current under the related-party standstill described above. Cash fell to $19.3 million from $24.4 million.

Management's liquidity statement is unqualified: "we believe that our current cash and cash flows provided by operating activities, and the net proceeds from our equity offerings and borrowing will be sufficient to meet our working capital needs in the next 12 months." Auditor Marcum Asia CPAs LLP issued a clean opinion on September 15, 2026 with no going-concern paragraph. That is a meaningful data point — but readers should note it rests substantially on a related party choosing not to call in $76 million.

Concentration is severe and getting worse on both sides

Two customers now account for 52% of revenue: Customer A at $26.2 million (27%) and Customer B at $24.4 million (25%), up from 26% and 14% respectively. The business section identifies the largest as Your-Buyer International Limited, a non-exclusive distributor covering the UK and France; the second is UK-only. Both are therefore exposed to the same UK regulatory regime that just banned disposables. One customer also represents 32% of net accounts receivable, up from 16%.

On the supply side, Shenzhen Yi Jia was 91% of total purchases in both years — $72.1 million of FY2026 purchases. Ispire's largest supplier, largest creditor, and controlling shareholder are the same economic interest.

One disclosure note worth flagging: the risk-factor section states the second-largest distributor "accounted for approximately 17% of revenue for the years ended June 30, 2026," while the business section says 25.5% and the audited concentration note says 25%. The audited figure is the one to use, but the inconsistency sits alongside management's conclusion that internal control over financial reporting was not effective as of June 30, 2026, due to a material weakness in "IT general controls regarding cyber security governance, logical access security and service organization management." Three prior-year material weaknesses — including insufficient US GAAP expertise, which had previously caused restatements — were remediated during FY2026.

What management is betting on

Ispire gave no revenue or earnings guidance. Three initiatives carry the forward story:

1. Malaysia manufacturing. On March 17, 2026 Ispire Malaysia received full and final licensure from Malaysia's Ministry of Investment, Trade and Industry to manufacture nicotine vapor products, replacing the interim license from May 2025. Six production lines are running; the company plans "adding up to 70 new lines at a second factory located nearby," expected "over the next 12 months." This is the only stated path to reducing the 91% dependence on the related-party supplier — and the only realistic path to paying down that $76.3 million rather than rolling it.
2. IKE Tech age-verification joint venture (40% owned). IKE is developing device-level age-gating for e-cigarettes. Two regulatory events during the year support the thesis: FDA draft guidance on March 11, 2026 explicitly recognized that device access restrictions such as "biometric authentication, geofencing, and continuous age verification" may factor into whether a flavored ENDS product meets the approval standard; and on May 5, 2026 the FDA authorized four flavored Glas products that carried point-of-use age-gating. The financial reality is earlier-stage: IKE generated $136,752 of revenue in FY2026 and a $2.3 million net loss, of which Ispire's share was $903,723. Ispire carries the investment at $8.6 million and still owes $3.5 million of its $9 million committed contribution.
3. Nicotine pouches. In August 2026 — after year-end — subsidiary Aspire Science signed a definitive agreement with Shandong Jincheng Pharmaceutical & Chemical to operate JinWu Health Limited, a JV owned 49% by Aspire Science and 51% by Jincheng, to develop, produce and sell nicotine pouch products. No financial terms were disclosed. Pouches are a genuinely growing category, but Ispire enters it as a minority partner with no disclosed committed capital or timeline.

Our read

The FY2026 numbers describe a controlled contraction, not a turnaround. The narrower loss is bought with $15.6 million of cost cuts, including an R&D budget reduced to $81,000; the revenue decline is partly self-inflicted (walking away from customers who do not pay) and partly external (UK disposables ban, European distributor caution). Both are rational responses, and the receivables discipline is the right call — but the arithmetic is unforgiving: at a 12.8% gross margin, $96 million of revenue produces $12.3 million of gross profit against $44.9 million of operating expenses. Even if credit losses fell to zero tomorrow, the remaining $24.2 million cost base would still exceed gross profit by roughly $12 million.

The three things that would change that math are volume recovery in Europe, a higher-margin mix (which requires the US cannabis channel to become creditworthy again, something largely outside Ispire's control), or manufacturing its own product in Malaysia at a better cost than it buys from Shenzhen Yi Jia. Only the third is meaningfully within management's hands, and it is the one with the least disclosed evidence so far — the filing gives no production volumes, no cost comparison, and no margin contribution from the Malaysian plant.

Meanwhile, the negative $29.2 million equity position and the $76.3 million related-party balance mean the company's continued operation depends on the forbearance of its controlling shareholder, who renewed a twelve-month standstill two days after fiscal year-end. That is not a hypothetical risk; it is the current funding structure. The stock closed at $1.12 on June 30, 2026, the last trading day of the fiscal year, against 57.8 million shares outstanding.

Source: Ispire Technology Inc. Form 10-K for the fiscal year ended June 30, 2026, filed with the SEC on September 15, 2026 (Accession No. 0001213900-26-100146).